MRI contrast firm Epix files IPO
Epix Medical of Cambridge, MA, has filed a registration statementwith the Securities and Exchange Commission for an initial publicoffering of two million shares of stock, plus an overallotmentoption of 300,000 shares. Epix, formerly known as Metasyn, isa
Epix Medical of Cambridge, MA, has filed a registration statementwith the Securities and Exchange Commission for an initial publicoffering of two million shares of stock, plus an overallotmentoption of 300,000 shares. Epix, formerly known as Metasyn, isa developer of targeted contrast agents, including MS-325, a gadolinium-basedagent for MR angiography of coronary and peripheral arteries.
Epix has licensed rights to MS-325 and other MRI vascular agentsin all countries except Japan to Mallinckrodt of St. Louis (SCAN10/9/96). MS-325 has entered phase I clinical trials, and proceedsfrom Epix's IPO will help fund that work and will be used forgeneral corporate purposes.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
